Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 10, 2013, Pages 2112-2120

  Yun, Fen ^a   Jia, Yongfeng ^a   Li, Xiuxia ^a   Yuan, Li ^b   Sun, Qinnuan ^a   Yu, Huiling ^a   Shi, Lin ^a   Yuan, Hongwei ^a  

^a AFFILIATED HOSPITAL OF INNER MONGOLIA MEDICAL UNIVERSITY   (China)

^b Heze Medical College   (China)

Author keywords

EGFR; Non small cell lung cancer (NSCLC); P AKT; PTEN; TGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; EGFR; FEMALE; GENETICS; HUMAN; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; NON-SMALL CELL LUNG CANCER (NSCLC); P-AKT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROGNOSIS; PTEN; SIGNAL TRANSDUCTION; TGF-Α;

EGFR; NON-SMALL CELL LUNG CANCER (NSCLC); P-AKT; PTEN; TGF-Α;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL DIFFERENTIATION; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84885356763     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Keith RL, Miller YE. Lung cancer chemoprevention: current status and future prospects. Nat Rev Clin Oncol 2013; 10: 334-43.
2. Kadara H, Wistuba II. Field cancerization in non-small cell lung cancer: implications in disease pathogenesis. Proc Am Thorac Soc 2012; 9: 38-42.
3. Salvesen HB, Werner HM, Krakstad C. PI3K Pathway in Gynecologic Malignancies. Am Soc Clin Oncol Educ Book 2013; 2013: 218-21.
4. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67-73.
5. Daniilidou K, Frangou-Plemenou M, Grammatikakis J, Grigoriou O, Vitoratos N, Kondi-Pafiti A. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study. J BUON 2013; 18: 195-201.
6. Duman BB, Sahin B, Acikalin A, Ergin M, Zorludemir S. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer. J BUON 2013; 18: 44-50.
7. Boespflug A, Couraud S, Bringuier PP, Isaac S, Gérinière L, Perrot E, Edery P, Durieu I, Souquet PJ. Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L. Lung Cancer 2013; 79: 318-20.
8. Rahmani A, Alzohairy M, Babiker AY, Rizvi MA, Elkarimahmad HG. Clinicopathological significance of PTEN and bcl2 expressions in oral squamous cell carcinoma. Int J Clin Exp Pathol 2012; 5: 965-71.
9. Ghita C, Vîlcea ID, Dumitrescu M, Vîlcea AM, Mirea CS, Aschie M, Vasilescu F. The prognostic value of the immunohistochemical aspects of tumor suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-67 in resected colorectal carcinoma. Rom J Morphol Embryol 2012; 53: 549-56.
10. Abdulkareem IH, Blair M. Effects of indomethacin on expression of PTEN tumour suppressor in human cancers. Niger Med J 2013; 54: 100-6.
11. Cheng T, Zhang JG, Cheng YH, Gao ZW, Ren XQ. Relationship between PTEN and Livin expression and malignancy of renal cell carcinomas. Asian Pac J Cancer Prev 2012; 13: 2681-5.
12. Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, Liu X, Liang DS, Lu YJ, Shan HL, Jiang HC. Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem 2012; 30: 631-41.
13. Akca H, Demiray A, Tokgun O, Yokota J. Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells. Lung Cancer 2011; 73: 302-9.
14. Koromilas AE, Mounir Z. Control of oncogenesis by eIF2a phosphorylation: implications in PTEN and PI3K-Akt signaling and tumor treatment. Future Oncol 2013; 9: 1005-15.
15. Dionysopoulos D, Pavlakis K, Kotoula V, Fountzilas E, Markou K, Karasmanis I, Angouridakis N, Nikolaou A, Kalogeras KT, Fountzilas G. Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma. Strahlenther Onkol 2013; 189: 202-14.
16. Pannain VL, Morais JR, Damasceno-Ribeiro O, Avancini-Alves V. Transforming growth factor aimmunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic liver tissue. Ann Hepatol 2012; 11: 495-9.
17. Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012; 14: 207-14.
18. Egleston BL, Meireles SI, Flieder DB, Clapper ML. Population-based trends in lung cancer incidence in women. Semin Oncol 2009; 36: 506-15.
19. Grudny J, Kolakowski J, Kruszewski M, Szopinski J, Sliwinski P, Wiatr E, Winek J, Zaleska J, Zych J, Roszkowski-Sliz K. Association of genetic dependences between lung cancer and chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2013; 81: 308-18.
20. Bettstetter M, Berezowska S, Keller G, Walch A, Feuchtinger A, Slotta-Huspenina J, Feith M, Drecoll E, Höfler H, Langer R. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum Pathol 2013; 44: 829-36.
21. Takeda H, Takigawa N, Ohashi K, Minami D, Kataoka I, Ichihara E, Ochi N, Tanimoto M, Kiura K. Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency. Exp Cell Res 2013; 319: 417-23.
22. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol 2012; 181: 401-12.
23. Im SA, Lee KE, Nam E, Kim DY, Lee JH, Han HS, Seoh JY, Park HY, Cho MS, Han WS, Lee SN. Potential prognostic significance of p18-5(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori 2005; 91: 513-21.
24. Panagiotou I, Tsiambas E, Lazaris AC, Kavantzas N, Konstantinou M, Kalkandi P, Ragkos V, Metaxas GE, Roukas DK, Vilaras G, Patsouris E. PTEN expression in non small cell lung carcinoma based on digitized image analysis. J BUON 2012; 17: 719-23.
25. Kim EJ, Jeong JH, Bae S, Kang S, Kim CH, Lim YB. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy. J Cell Biochem 2013; 114: 1248-56.
26. Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Müller V, Pantel K, Wikman H. Frequent Genetic Alterations in EGFR- and HER2-Driven Pathways in Breast Cancer Brain Metastases. Am J Pathol 2013; 183: 83-95.